SOUTH SAN FRANCISCO, Calif., March 25, 2022 (GLOBE NEWSWIRE) — Fluidigm Corporation (FLDM, Financial) announced today that it has convened and then adjourned, without dealing with other business, the special meeting of shareholders of the company (the “Special Meeting”) in order to give shareholders more time to vote on the previously announced strategic capital injection from leading life sciences investors Casdin Capital, LLC (“Casdin”) and Viking Global Investors LP (“Viking”). The special meeting has been adjourned until 9:00 a.m. Pacific time on April 1, 2022. All shareholders of record at the close of business on February 18, 2022 retain the right to vote for their shares at the special meeting. The special meeting will be held at the Genesis SSF Performing Arts Center, located at 1 Tower Place, South San Francisco, CA 94080.
As previously announced on January 24, 2022, following shareholder approval and satisfaction of closing conditions, Fluidigm expects to receive a total investment of $250 million, including $25 million previously raised in the form of term loans. , Casdin and Viking, which will significantly advance the Company’s mission through new organic and inorganic growth initiatives while optimizing its cost structure. Upon closing of the investment, Fluidigm will change its name to Standard BioTools Inc., better reflecting its ambitions to become a critical solutions partner for the life sciences industry focused on the highest growth areas of discovery and biological development.
The Board of Directors of the Company unanimously recommends that shareholders vote “FOR” all the proposals at the special meeting. Your vote is very important regardless of how many common shares you own.
The Company will continue to solicit proxies from its shareholders with respect to the Special Meeting. Shareholders on the record date of February 18, 2022 who have not yet voted are urged to submit their proxies as soon as possible. Valid proxies submitted by shareholders prior to the adjourned special meeting will continue to be valid for the purposes of the reconvened special meeting.
Fluidigm stockholders who need assistance completing the proxy card, need additional copies of the proxy materials, or have questions regarding the special meeting can contact Fluidigm’s proxy attorney:
200 Broadacres Drive
Bloomfield, New Jersey 07003
Jefferies LLC is financial advisor to Fluidigm and Wilson Sonsini Goodrich & Rosati, Professional Corporation is legal advisor.
Centerview Partners LLC is the financial advisor to Casdin and Viking. Legal advisors are Paul, Weiss, Rifkind, Wharton & Garrison LLP serving Casdin and Kirkland & Ellis LLP serving Viking.
Fluidigm (FLDM, Financial) focuses on the most pressing translational and clinical research needs, including cancer, immunology and immunotherapy. Using proprietary CyTOF® and microfluidic technologies, we develop, manufacture and market multi-omics solutions to gain meaningful insights into health and disease, identify biomarkers to inform decisions and accelerate the development of more effective therapies. . Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide. With them, we strive to improve everyone’s quality of life. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation or its subsidiaries in the United States and/or other countries. All other trademarks are the exclusive property of their respective owners. Fluidigm products are provided for research purposes only. Not for use in diagnostic procedures.
Fluidigm uses its website (fluidigm.com), investor website (investors.fluidigm.com), company Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm) and the LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels for the distribution of information about its products, its planned financial and other announcements, its participation in upcoming investor and industry conferences, and other matters. This information may be considered material information and Fluidigm may use these channels to comply with its disclosure obligations under the FD Regulation. Accordingly, investors should monitor Fluidigm’s website and our social media accounts in addition to monitoring its press releases, SEC filings, public conference calls and webcasts.
About Casdin Capital
Casdin Capital, LLC is a New York-based research investment firm focused on innovations that are currently reshaping life sciences and healthcare. Founded in 2011 and committed to long-term returns and disruptive technologies, Casdin Capital is a trusted investor-partner in private and public companies, collaborating with industry leaders to fuel their visions, adding energy, knowledge and experience to more than $3 billion under management. For more information, please visit casdincapital.com.
About Viking Global Investors
Founded in 1999, Viking is a global investment management firm that manages approximately $48 billion in capital for its investors. It has offices in Greenwich, New York, Hong Kong, London and San Francisco and is registered as an investment adviser with the United States Securities and Exchange Commission. For more information, please visit www.vikingglobal.com.
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: Fluidigm’s expectations that the transactions described in this communication (the “Transaction”) will accelerate the growth and innovation; expectations regarding portfolio expansion and the advancement of Fluidigm’s mission; optimization of the cost structure; expectations for the development of transformative biologics, improved revenues and profitability and increased shareholder value; the expected timing and closing of the transaction; expectations regarding the Company’s brand and name; and other expectations for Fluidigm following the closing of the Transaction. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from results currently anticipated, including, but not limited to, risks related to: the potential adverse effects of the coronavirus pandemic our business and results of operations; any failure to obtain the required shareholder approval for the transaction; the possibility that the conditions to the closing of the Transaction will not be satisfied; potential litigation related to the Transaction; uncertainties as to the timing of the Transaction; the ability of each party to complete the Transaction; possible disruption related to the Transaction of Fluidigm’s current plans and operations, including through the loss of customers, suppliers and employees; changes in Fluidigm’s business or external market conditions; uncertainties in contractual relationships; customers and potential customers continuing to reduce or suspend their activities using our products; our ability and/or the ability of research institutions using our products and technology to obtain and maintain FDA Emergency Use Clearance and any other clearances or approvals required to use our products and technology for any purpose diagnostic testing; challenges inherent in developing, manufacturing, launching, marketing and selling new products; interruptions or delays in the supply of components or materials for, or manufacture of Fluidigm products; reliance on capital equipment sales for a significant portion of revenue in each quarter; seasonal variations in customer operations; unexpected increases in costs or expenses; uncertainties in contractual relationships; reductions in research and development expenditure or changes in budget priorities by customers; Fluidigm’s research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacture of Fluidigm products; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. Information about these additional risks and uncertainties and other information affecting Fluidigm’s business and results of operations is contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and its other filings. filed with the Securities and Exchange Commission (the “SECOND”). These forward-looking statements speak only as of the date of this communication. Fluidigm disclaims any obligation to update these forward-looking statements, except as required by law.
650 243 6621
415 389 6400